(heathermowbray@caixin.com) Related: Medical Robot Maker Finds Elixir in STAR Board’s Market Reforms
It may still be losing money, but Chinese investors are still seeing plenty of potential in a specia
热评:
林博士接受美国食品药品监督管理局(Food and Drug Administration, FDA)的委托,调查为何人们喝了一种叫做“Elixir Sulfanilamide”(即磺胺)的药物后,死
, the elixir that provided the China Kool-Aid was the P2P lending business model. The model is pretty
Elixir pharmaceutical,但因临床试验失败而告吹。他目前再度投资了一家以衰老细胞作为靶点研发代谢疾病新疗法的企业, Unity Biotechnology 。 医疗科技日新月异、发展迅
败的案例,比如抗衰老公司Elixir pharmaceutical就因为临床的失败中途关门。不过,这并没有浇灭他对于抗衰老药物研发的兴趣,他目前所投资的Unity Biotechnology公司就是目
Biotech startup BeiGene Ltd. is aiming to raise about $1 billion through a public listing in Hong Ko
, as a multi-purpose health elixir. Bottles of the dark-red liquid sell for around 290 yuan ($46
of symptoms, making it an “elixir” for doctors. However, Ji argued that there aren’t solid lab results
图片
视频
It may still be losing money, but Chinese investors are still seeing plenty of potential in a specia
热评:
林博士接受美国食品药品监督管理局(Food and Drug Administration, FDA)的委托,调查为何人们喝了一种叫做“Elixir Sulfanilamide”(即磺胺)的药物后,死
热评:
, the elixir that provided the China Kool-Aid was the P2P lending business model. The model is pretty
热评:
Elixir pharmaceutical,但因临床试验失败而告吹。他目前再度投资了一家以衰老细胞作为靶点研发代谢疾病新疗法的企业, Unity Biotechnology 。 医疗科技日新月异、发展迅
热评:
败的案例,比如抗衰老公司Elixir pharmaceutical就因为临床的失败中途关门。不过,这并没有浇灭他对于抗衰老药物研发的兴趣,他目前所投资的Unity Biotechnology公司就是目
热评:
Biotech startup BeiGene Ltd. is aiming to raise about $1 billion through a public listing in Hong Ko
热评:
, as a multi-purpose health elixir. Bottles of the dark-red liquid sell for around 290 yuan ($46
热评:
of symptoms, making it an “elixir” for doctors. However, Ji argued that there aren’t solid lab results
热评: